Navigation Links
Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
Date:5/20/2008

rcentage of men who received this treatment maintained normal testosterone levels while receiving an injection every 10 weeks. This form of testosterone treatment would thus require only five injections per year. This would be an appealing alternative for many men, who may object to existing testosterone treatments such as twice-monthly injections or daily skin application of gels or patches."

About the Study

This Phase III study was a multi-center, open-label, randomized US trial designed to assess the pharmacokinetics, safety, and efficacy of NEBIDO in men with primary or secondary hypogonadism. The trial enrolled a total of 130 hypogonadal men (serum testosterone below 300 ng/dL, at least 18 years of age) that met the study inclusion criteria. Patients received injections of 750 mg of NEBIDO at baseline, week 4, and week 14 of the study, and were followed for an additional 10 weeks. Of the 130 men who participated in the trial, 117 patients were eligible for pharmacokinetics evaluations.

In the study, pharmacokinetic objectives were achieved, with 94 percent of patients reaching and maintaining normal serum testosterone levels. Additionally, secondary endpoints of mood and sexual function also improved. The most commonly reported possibly-related adverse events in the trial were acne (4.6 percent), fatigue (3.1 percent), and injection site pain (3.1 percent).

About NEBIDO

NEBIDO(R) is a long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism. NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About Hypogonadism

Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Today, there are an estimate
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
2. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Announces Submission of New Drug Application
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
(Date:10/30/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues, today announced today that ... released on Thursday, November 6, 2014, and that the ... at 1:30 p.m. PST that afternoon. Management will provide ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Replacing both knees in one surgery, or simultaneous ... fewer prosthetic joint infections as well as other revision ... total knee replacements performed in two separate procedures. However, ... of adverse cardiovascular outcomes within 30 days, according to ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... of the first patients treated with Zimmer MotionLoc™ Screws ... Screw is Zimmer Trauma,s latest advancement in locking plate technology and ... NCB ® Polyaxial Locking Plate System.   The ...
Cached Medicine Technology:Two Knee Replacements May Be Better Than One 2Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation 2Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation 3
(Date:10/30/2014)... Graphics, coding, typography and search engine ... craft of web design and require thorough knowledge to ... solution to create a website can be as easy ... customer reviews and Facebook posts all accumulate on a ... next evolution of how a business can develop a ...
(Date:10/30/2014)... Austin, TX (PRWEB) October 30, 2014 ... is gifting PreD Store shoppers with a ... taken before meals to reduce post-meal blood sugar spikes. ... overall health is an important part of a diabetes ... on orders will receive one complimentary tube of sugardown. ...
(Date:10/30/2014)... Haelle HealthDay Reporter , ... 100 genes have been identified that appear linked to ... researchers say they are on their way to discovering ... the disorder. Autism spectrum disorders include a range ... and repetitive behaviors. An estimated one in 68 U.S. ...
(Date:10/30/2014)... 2014 Horse Sense & Sensitivity ... to special needs individuals in the Jacksonville area, will ... 15 from 10-2:00 p.m. at Bailey's Farm (2202 Bishop ... the public and is designed to raise awareness and ... the HSS Round-Up is free. Ticket purchases will be ...
(Date:10/30/2014)... South Carolina (PRWEB) October 30, 2014 ... and should be more vigorously exercised to help maintain ... recently authored the book ‘Dementia Express: Lose Your Memory ... book uses counterintuitive reasoning and sometimes conflicting attitudes to ... course for the mind, a reader must decipher the ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
... as the incidence is likely to increase in the ... the course of Alzheimer's disease. There is a special ... messenger and this chemical//is regulated by a drug called ... enabled by the chemical glutamate. This happens when glutamate ...
... indicates lack of protein to development of cancer. Cells without ... either kill a cell or keep it from growing. However ... are able to multiply creating tumors. Researchers indicated that loss ... a normal cell the chance to change into a cancer ...
... In a recent study which examined the snoring habits ... them. People with chronic(15 headaches per month) daily headache ... chronic snorers than the people with occasional(104 headaches per ... and 65. When the researchers analysed people, those with ...
... indicates that Negative exercise electrocardiograph tests should ... of hypertensive patients with chest pain. Even ... risk, positive findings could not distinguish levels ... pharmacological stress echocardiography yielded diagnostic and prognostic ...
... first country to contain its SARS outbreak. Vietnam had five ... Hanoi's international hospital. There was about sixty three people affected ... there by reducing the rate of infection and keeping SARS ... have been reported from Vietnam since April 8.// The country ...
... in India went up to 10, authorities are not confident ... shown a far higher recovery rate than the rest of ... medical care provided to SARS patients. Even what we call ... are only between 60 and 65 per cent accurate according ...
Cached Medicine News:
BD Vacutainer® Fluoride Tubes - Glass...
VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: